Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  BioLineRX Ltd.    BLRX   IL0011015182

BIOLINERX LTD.

(BLRX)
My previous session
Most popular
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
03/13/2019 03/14/2019 03/17/2019 03/18/2019 03/19/2019 Date
160.5(c) 160.7(c) 162.3(c) 164.7(c) 164.5(c) Last
220 618 119 321 158 233 121 785 27 179 Volume
-0.43% +0.12% +1.00% +1.48% -0.12% Change
More quotes
Company
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to... 
Sector
Biotechnology & Medical Research
Calendar
03/19 | 03:20pmPresentation
More about the company
Latest news on BIOLINERX LTD.
03/14BIOLINERX : to Present at the 29th Annual Oppenheimer Healthcare Conference
PR
02/07BIOLINERX : Announces Closing of $15.4 Million Underwritten Public Offering of i..
PU
02/05BIOLINE RX : BioLineRx Announces Pricing of $15.4 Million Underwritten Public Of..
AQ
02/04BIOLINE RX : BioLineRx Announces Proposed Underwritten Public Offering of its Am..
AQ
02/04BIOLINERX : Receives Orphan Drug Designation From the FDA for its Lead Therapeut..
PR
2018BIOLINERX : Begins Triple Combination Arm of Phase 2a Pancreatic Cancer Trial
AQ
2018MERCK AND : Results of triple combination arm of BL-8040, KEYTRUDA® and chemoth..
AQ
2018BIOLINERX : Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KE..
PR
2018BIOLINERX : to Host Investor and Analyst Breakfast Meeting on December 11, 2018 ..
PU
2018BIOLINERX : Announces Receipt of FDA Biological Product Designation for Novel Ca..
PR
More news
Analyst Recommendations on BIOLINERX LTD.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart BIOLINERX LTD.
Duration : Period :
BioLineRX Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOLINERX LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Managers
NameTitle
Philip Adam Serlin Chief Executive Officer & Head-Investor Relations
Aharon Schwartz Chairman
Mali Zeevi Chief Financial Officer
Abi Vainstein-Haras Vice President-Clinical Development
Sorani Ella Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOLINERX LTD.1.10%66
IQVIA HOLDINGS INC23.16%28 301
CELLTRION, INC.--.--%22 761
LONZA GROUP16.88%22 156
INCYTE CORPORATION34.72%18 327
SEATTLE GENETICS, INC.28.59%11 793